203 related articles for article (PubMed ID: 31654094)
21. Blockade of Janus kinase-2 signaling ameliorates mouse liver damage due to ischemia and reperfusion.
Freitas MC; Uchida Y; Zhao D; Ke B; Busuttil RW; Kupiec-Weglinski JW
Liver Transpl; 2010 May; 16(5):600-10. PubMed ID: 20440769
[TBL] [Abstract][Full Text] [Related]
22. Signal transducer and activator of transcription (STAT) 1 and STAT3 are expressed in the human ovary and have Janus kinase 1-independent functions in the COV434 human granulosa cell line.
Frost ER; Ford EA; Peters AE; Reed NL; McLaughlin EA; Baker MA; Lovell-Badge R; Sutherland JM
Reprod Fertil Dev; 2020 Aug; 32(12):1027-1039. PubMed ID: 32758351
[TBL] [Abstract][Full Text] [Related]
23. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
[TBL] [Abstract][Full Text] [Related]
24. HOTAIR regulates lipopolysaccharide-induced inflammatory response in hepatocytes.
Zhang J; Chen M; Zhai Y; Fu Y
J Cell Physiol; 2020 May; 235(5):4247-4255. PubMed ID: 31621909
[TBL] [Abstract][Full Text] [Related]
25. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
Singer JW; Al-Fayoumi S; Taylor J; Velichko S; O'Mahony A
PLoS One; 2019; 14(9):e0222944. PubMed ID: 31560729
[TBL] [Abstract][Full Text] [Related]
26. JAK1/2 inhibition impairs the development and function of inflammatory dendritic epidermal cells in atopic dermatitis.
Klaeschen AS; Nümm TJ; Herrmann N; Leib N; Maintz L; Sakai T; Wenzel J; Bieber T
J Allergy Clin Immunol; 2021 Jun; 147(6):2202-2212.e8. PubMed ID: 33338537
[TBL] [Abstract][Full Text] [Related]
27. Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models.
Huarte E; Peel M; Juvekar A; Dubé P; Sarah S; Stephens L; Stewart B; Long B; Czerniak P; Oliver J; Smith P
Immunotherapy; 2021 Aug; 13(12):977-987. PubMed ID: 34184542
[No Abstract] [Full Text] [Related]
28. Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation.
Mortara A; Mazzetti S; Margonato D; Delfino P; Bersano C; Catagnano F; Lauriola M; Grosso P; Perseghin G; Ippoliti G
Clin Transl Sci; 2021 May; 14(3):1062-1068. PubMed ID: 33403775
[TBL] [Abstract][Full Text] [Related]
29. Ruxolitinib.
Becker H; Engelhardt M; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2014; 201():249-57. PubMed ID: 24756798
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice.
Maschalidi S; Sepulveda FE; Garrigue A; Fischer A; de Saint Basile G
Blood; 2016 Jul; 128(1):60-71. PubMed ID: 27222478
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-1beta stimulates acute phase response and C-reactive protein synthesis by inducing an NFkappaB- and C/EBPbeta-dependent autocrine interleukin-6 loop.
Kramer F; Torzewski J; Kamenz J; Veit K; Hombach V; Dedio J; Ivashchenko Y
Mol Immunol; 2008 May; 45(9):2678-89. PubMed ID: 18262272
[TBL] [Abstract][Full Text] [Related]
32. Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease.
Ryu DB; Lim JY; Kim TW; Shin S; Lee SE; Park G; Min CK
Exp Hematol; 2021 Jun; 98():36-46.e2. PubMed ID: 33811972
[TBL] [Abstract][Full Text] [Related]
33. JAK1/STAT3 activation directly inhibits IL-12 production in dendritic cells by preventing CDK9/P-TEFb recruitment to the p35 promoter.
Wagner AH; Conzelmann M; Fitzer F; Giese T; Gülow K; Falk CS; Krämer OH; Dietrich S; Hecker M; Luft T
Biochem Pharmacol; 2015 Jul; 96(1):52-64. PubMed ID: 25931145
[TBL] [Abstract][Full Text] [Related]
34. Baicalein reduces lipopolysaccharide-induced inflammation via suppressing JAK/STATs activation and ROS production.
Qi Z; Yin F; Lu L; Shen L; Qi S; Lan L; Luo L; Yin Z
Inflamm Res; 2013 Sep; 62(9):845-55. PubMed ID: 23743662
[TBL] [Abstract][Full Text] [Related]
35. Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat.
Yao L; Mustafa N; Tan EC; Poulsen A; Singh P; Duong-Thi MD; Lee JXT; Ramanujulu PM; Chng WJ; Yen JJY; Ohlson S; Dymock BW
J Med Chem; 2017 Oct; 60(20):8336-8357. PubMed ID: 28953386
[TBL] [Abstract][Full Text] [Related]
36. CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes.
Migita K; Komori A; Torigoshi T; Maeda Y; Izumi Y; Jiuchi Y; Miyashita T; Nakamura M; Motokawa S; Ishibashi H
Arthritis Res Ther; 2011 May; 13(3):R72. PubMed ID: 21548952
[TBL] [Abstract][Full Text] [Related]
37. Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis.
Scuron MD; Fay BL; Connell AJ; Peel MT; Smith PA
Front Immunol; 2020; 11():620098. PubMed ID: 33658996
[TBL] [Abstract][Full Text] [Related]
38. Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2.
Song Z; Liu X; Zhang W; Luo Y; Xiao H; Liu Y; Dai G; Hong J; Li A
J Transl Med; 2022 Apr; 20(1):157. PubMed ID: 35382859
[TBL] [Abstract][Full Text] [Related]
39. Impact of JAK/STAT inhibitors on human monocyte-derived-macrophages stimulated by cigarette smoke extract and lipopolysaccharide.
Verres Y; da Silva CO; Aljebawi B; Bodin A; Barreto E; Lagente V; Victoni T
Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1187-1196. PubMed ID: 35876719
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P
Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
